Sarepta Therapeutics (SRPT)
(Delayed Data from NSDQ)
$142.24 USD
-0.80 (-0.56%)
Updated Jul 31, 2024 04:00 PM ET
3-Hold of 5 3
D Value D Growth B Momentum D VGM
Brokerage Reports
Sarepta Therapeutics, Inc. [SRPT]
Reports for Purchase
Showing records 21 - 40 ( 669 total )
Company: Sarepta Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Sarepta Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Sarepta Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Efficacy Supplement to ELEVIDYS'' BLA Accepted; Review Goal Date of June 21
Provider: Wedbush Securities Inc.
Analyst: ARGYRIDES A
Company: Sarepta Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Sarepta Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Optimized Entry and Exit Levels for SRPT 21224
Provider: Stock Traders Daily
Analyst: Research Department
Company: Sarepta Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Sarepta Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Sarepta Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Sarepta Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Sarepta Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Topline Part B MOMENTUM Data for SRP-5051; Near-Term Focus Remains on ELEVIDYS
Provider: Wedbush Securities Inc.
Analyst: ARGYRIDES A
Company: Sarepta Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Optimized Entry and Exit Levels for SRPT 12224
Provider: Stock Traders Daily
Analyst: Research Department
Company: Sarepta Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
2024 Outlook on Covered Companies Takeaways from Annual SF Biotech Meetings
Provider: Wedbush Securities Inc.
Analyst: ARGYRIDES A
Company: Sarepta Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Sarepta Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Sarepta Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Sarepta Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
ELEVIDYS Exceeds Q4/FY23 Expectations, Potential Label Expansion on the Horizon
Provider: Wedbush Securities Inc.
Analyst: ARGYRIDES A
Company: Sarepta Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Sarepta Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Optimized Entry and Exit Levels for SRPT 1224
Provider: Stock Traders Daily
Analyst: Research Department
Company: Sarepta Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Sarepta Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
ELEVIDYS Efficacy Supplement PMR Submitted; Unlocking Additional Value in ''24
Provider: Wedbush Securities Inc.
Analyst: ARGYRIDES A